3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Cisplatin
6
Paclitaxel
4
pembrolizumab
3
Fluorouracil
3
Carboplatin
3
tislelizumab
2
Taxes
2
Radiotherapy
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
Injections
2
Capecitabine
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
lenvatinib
1
durvalumab
1
cixutumumab
1
apatinib
1
Tegafur
1
Surgical Procedures, Operative
1
Saline Solution
1
Radiation
1
Levoleucovorin
1
Laparoscopy
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Fulvestrant
1
Docetaxel
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.